Letter to the Editor

Response to: Comment on “Soluble Urokinase-Type Plasminogen Activator Receptor Plasma Concentration May Predict Susceptibility to High Altitude Pulmonary Edema”

Table 1

Development of suPAR, CRP, and IL-6 plasma concentration during 48 hours of exposure to 4559 m.

High altitude, 24 hoursHigh altitude, 72 hours value, delta median (95% CI)

suPAR [ng/ml]
Entire sample ()2.27 (2.20)2.08 (2.00), Δ0.10 (−0.05–0.20)
No steroids ()2.13 (2.00)2.03 (1.90), Δ-0.15 (−0.35–0.10)
Therapy ()2.33 (2.25)2.11 (2.05), Δ0.20 (0.00–0.30)
CRP [mg/l]
Entire sample ()3.57 (2.20)3.43 (2.60), Δ0.10 (−0.75–1.40)
No steroids ()1.81 (1.60)2.76 (2.60), Δ-1.13 (−2.70–0.05)
Therapy ()4.45 (2.50)3.76 (2.50), Δ1.25 (−0.30–2.40)
IL-6 [ng/l]
Entire sample ()2.71 (2.05)1.51 (0.73), Δ1.04 (0.23–2.60)
No steroids ()2.45 (2.05)2.67 (1.75), Δ0.33 (−3.19–1.25)
Therapy ()2.91 (2.21)0.64 (0.34), Δ2.18 (0.69–4.06)

Comparison of inflammatory marker plasma concentration at 24 versus 72 hours was performed using related sample Wilcoxon signed rank test. Values are given as median (IQR). Delta median corresponds to the median of the difference between samples from both timepoints. suPAR: soluble urokinase-type plasminogen activator receptor; IL-6: interleukin-6; CRP: c-reactive protein; CI: confidence interval.